The P2X7 receptor regulates cell survival, migration and invasion of pancreatic ductal adenocarcinoma cells
© Giannuzzo et al. 2015
Received: 20 April 2015
Accepted: 18 November 2015
Published: 25 November 2015
Pancreatic ductal adenocarcinoma (PDAC) is presently one of the cancers with the worst survival rates and least effective treatments. Moreover, total deaths due to PDAC are predicted to increase in the next 15 years. Therefore, novel insights into basic mechanism of PDAC development and therapies are needed. PDAC is characterized by a complex microenvironment, in which cancer and stromal cells release different molecules, such as ATP. ATP can be transported and/or exocytosed from active cancer cells and released from dying cells in the necrotic core of the cancer. We hypothesized that one of the ATP receptors, the P2X7 receptor (P2X7R) could be an important player in PDAC behaviour.
We determined the expression (real time PCR and Western blot) and localization (immunofluorescence) of P2X7R in human PDAC cell lines (AsPC-1, BxPC-3, Capan-1, MiaPaCa-2, Panc-1) and a “normal” human pancreatic duct epithelial cell line (HPDE). The function of P2X7R in proliferation (BrdU assay), migration (wound assay) and invasion (Boyden chamber with matrigel) was characterized. Furthermore, we studied P2X7R-dependent pore formation (YoPro-1 assay) and cell death (caspase and annexin V / propidium iodide assays).
We found higher expression of P2X7R protein in PDAC compared to HPDE cells. P2X7R had notable disparate effects on PDAC survival. Firstly, high concentrations of ATP or the specific P2X7R agonist, BzATP, had cytotoxic effects in all cell lines, and cell death was mediated by necrosis. Moreover, the P2X7R–pore antagonist, A438079, prevented ATP-induced pore formation and cell death. Second, in basal conditions and with low concentrations of ATP/BzATP, the P2X7R allosteric inhibitor AZ10606120 reduced proliferation in all PDAC cell lines. P2X7R also affected other key characteristics of cancer cell behavior. AZ10606120 reduced cell migration and invasion in PDAC cell lines compared to that of untreated/vehicle-treated control cells, and stimulation with sub-millimolar concentrations of ATP or BzATP substantially increased cell invasion.
PDAC cell lines overexpress P2X7R and the receptor plays crucial roles in cell survival, migration and invasion. Therefore, we propose that drugs targeting P2X7R could be exploited in therapy of pancreatic cancer.
Pancreatic Ductal Adenocarcinoma (PDAC) is an aggressive and devastating disease . The estimated 5-year survival rate is less than 5 %, even in regions of the world with the best healthcare, and incidence is expected to rise with ageing population . In USA, total deaths due to pancreatic cancer (where PDAC constitute about 90 % of these cancers), are projected to increase dramatically and become the second leading cause of cancer-related deaths before 2030 . Due to redundancy of pancreatic function, the disease is detected relatively late, when the local tumor has advanced or the disease has disseminated. Most conventional chemotherapies fail to give substantial responses in PDAC and one of the important factors may be the unusual and impermeable tumor microenvironment (TME). PDAC is a solid tumor rich in stromal cells and exhibiting marked desmoplasia, stiffness and poor vascularization . The cellular compartment of TME includes, apart from cancer cells, pancreatic stellate cells (PSCs), cancer associated fibroblasts, various immune cells, endothelial cells and pericytes. The acellular component includes, extracellular matrix (ECM) components and matrix-degrading enzymes, as well as a number of growth factors and cytokines , autocrine/paracrine factors, metabolites and ions. In the complex TME, cancer and stromal cells release a variety of molecules that can support tumor proliferation, migration, invasion and immune system escape . One relevant and multifunctional candidate is ATP, which can be released from metabolically active cancer cells and other cells to the extracellular space via plasma membrane transport systems or by exocytosis, and from dying cells in the tumor necrotic area . It is difficult to detect intra-tumor ATP levels due to up-regulated ecto-nucleotidases and hydrolysis of ATP to adenosine . Using plasma membrane luciferase and bioluminescence detection, it has been possible to detect extracellular ATP at hundreds micromolar concentration in tumor interstitium in melanoma and ovarian cancer . However, methods to monitor ATP concentration gradients across tissues or tumors are not yet available.
ATP and other extracellular nucleotides activate two families of receptors: P2X receptors, a family of ligand-gated receptor channels; and P2Y receptors, G protein-coupled receptors . One of the most remarkable purinergic receptors is the P2X7 receptor, because it has a crucial role in several physiological and pathophysiological processes and because the receptor is highly polymorphic, and single nucleotide polymorphism (SNPs) are associated with several diseases including central nervous system diseases, pain, osteoporosis, cancer and inflammation . There are nine different human splice variants - named P2X7A–J (P2X7B, P2X7C, P2X7E, P2X7G and P2X7J lack of C-terminal) , and isoforms A and B are the most studied. P2X7 receptor (P2X7R) is a two membrane-spanning domain protein that forms trimers and at submillimolar extracellular ATP concentrations behaves as a cation channel and elicits a number of cellular responses. An extensively documented and well established role of the receptor is in cell death. At millimolar ATP concentrations P2X7R mediates plasma membrane permeabilization, due to formation of pores permeable to large molecules (up to 900 Da) [11, 12], and this leads to apoptotic/necrotic events [13, 14]. Recently, several reports showed a novel characteristic of P2X7R, namely that it can increase cell proliferation [15, 16]. This effect may be elicited at basal or low ATP concentrations [17, 18] and/or depends on isoforms expression .
The P2X7 receptor is over-expressed in many cancer types [20–22], and potentially the unusual double role of P2X7R in cancer cell proliferation and cell death and modulation by immune system could find applications in cancer therapy. Two hypotheses regarding the roles of P2X7R are proposed: either the receptor can be considered as an anti-tumor protein inducing cell death in cancer cells [23–25]; or the receptor is a pro-cancerous protein increasing tumor growth and invasion [26, 27]. Given that the TME is likely to exhibit ATP concentration gradients, the receptor could serve different functions in different locations in the tumor .
In pancreas, P2X7R is expressed in rodent duct cells (but not acinar cells) and in human PDAC cells grown as epithelial monolayers, and in both the receptor has a role in calcium signaling and regulation of ion transport and secretion [28–30]. Moreover, P2X7R is expressed in pancreatic stellate cells (PSCs) , which are the major contributors to the abundant stromal/desmoplastic reaction that characterizes pancreatic cancer . The role of P2X7R in PSCs is to support proliferation and/or cell death depending on extracellular ATP concentrations . One study utilizing patient tissues reported that there was a tendencial increase of P2X7R protein level in chronic pancreatitis and pancreatic cancer compared to normal tissues .
In light of the fact that this receptor is important for cell survival and may be overexpressed in pancreatic cancer, we need to understand its role in PDAC behavior. The aim of this study was to use a simple in vitro cell model to detect the expression of P2X7R in PDAC cell lines and to clarify whether it affects PDAC behavior such as cell proliferation, cell death, migration and invasion. Knowledge gained from this study can form the basis for more advanced drug testing in in vivo pancreas cancer models.
Expression and localization of P2X7 receptor in PDAC and control human pancreatic duct cell lines
Five PDAC cell lines were used: AsPC-1, BxPC-3, Capan-1, MiaPaCa-2 and Panc-1. They are genotypically and phenotypically heterogeneous and they are representative of different stages of pancreatic cancer. For example, Panc-1 is derived from epithelioid pancreatic carcinoma, MiaPaCa-2 is a poorly differentiated cell line , Capan-1 is a well differentiated cell line derived from liver metastasis , and AsPC-1 is a poorly differentiated cell line derived from nude mouse xenografts initiated with cells from the ascites of a patient with pancreatic cancer . All cell lines have mutations in TP53 and KRAS genes, except for BxPC-3 which has wild type KRAS. HPDE, human “normal” pancreatic duct epithelial cell line, transformed using HPV16-E6E7  was used as control.
Primers used for RT-PCR and Real Time PCR on PDACs and HPDE
β actin FW
β actin RW
Protein expression of the full length P2X7R A isoform and the C-terminus truncated B isoform was determined using Western blot and immunolocalization (Fig. 1b-c). Figure 1b shows two bands, often seen by other researchers, and the lower band may correspond to the isoform H. The band at 70 kDa, corresponding to the isoform A, appears more abundant in all PDAC cell lines compared to control HPDE cells, but significant increase is detected only for Capan-1 and Panc-1. Figure 1c shows that there was a slightly reduced, but not significant, expression of the 42 kDa band that possibly corresponds to the isoform B in AsPC-1, BxPC-3 and Panc-1; and there is significantly lower expression in MiaPaCa-2 compared to HPDE cells.
P2X7R affects cell proliferation and cell death
In addition to caspase 3/7 assay, an Annexin V-488/propidium iodide (PI) assay was performed (Fig. 6b). Panc-1 cells were incubated with 1 mM ATP (20 h) and images in Fig. 6b show that a number of cells had red nuclei (PI), indicating that the cell membrane was permeabilized as in cells undergoing necrosis, and green Annexin V, indicating phosphatidyl serine exposure on cell surface. The transmission image also shows disrupted cells with uneven surface and nuclear swelling, also indicating a necrotic type of death.
P2X7R inhibitors have small effect on pore formation
P2X7R increases cell migration and invasion
This study shows that pancreatic ductal adenocarcinoma cells express P2X7 receptors, which regulate PDAC cell behavior with respect to cell proliferation and cell death, as well as in cell migration and invasion.
P2X7R is expressed in pancreatic cells of ductal origin at the mRNA and protein levels (Figs. 1 and 2). Interestingly, rodent pancreatic acinar cells do not seem to express mRNA for P2X7R , although recent studies in pancreatic cancer field implicate transdifferentiation of acinar cells to duct cells as an important process in PDAC development . In pancreatic duct cells, mRNA for P2X7R has a lower expression in all PDAC cell lines compared to HPDE cells (Fig. 1a), although we cannot be absolutely sure that HPDE cells are a faithful representative of healthy pancreatic ducts. Similar lower expression of receptor transcripts was found in uterine epithelial cancer compared to healthy controls . In contrast, a number of other cancers types show increased mRNA levels for P2X7R compared to the normal tissues [46, 47]. Importantly, we find that the P2X7RA protein level was higher in PDAC cell lines compared HPDE (Fig. 1b). The discrepancy between mRNA and protein levels could be due to the fact that we detected transcripts from several isoforms (as it is impossible to design qPCR primers specific only for the isoform A), but we quantified the protein levels of the most easily detectable and studied isoform A (and B).
Although PDAC cells express other P2X and P2Y receptors (Additional file 1: Figure S1), we have several lines of evidence to demonstrate remarkable functionality of the P2X7 receptor. Stimulation with increasing exogenous ATP concentrations resulted in a reduction of BrdU incorporations in all cell lines (Figs. 3 and 5), and similar results were also obtained with stimulation with BzATP (Fig. 4). BzATP is considered as the most potent agonist for P2X7 receptors, although we cannot exclude contributions from other P2 receptors, which are activated at lower ATP concentration, or that BzATP activates potentially other receptors (e.g. P2X1 and P2X4 ). Nevertheless, we interpret these data to indicate the classical role of P2X7 receptor in cell death induced by high ATP concentrations and will return to this topic in more detail below. An additional argument for P2X7R functionality is the effect of two specific receptor inhibitors, AZ10606120 and A438079, which had different effects on PDAC behavior.
One of the best documented roles of P2X7R is pore formation and apoptosis/cell death . We found that high concentrations of ATP caused pore formation in PDAC cell lines, as assayed by YoPro-1 uptake (Fig. 7). The competitive antagonist A438079, which is known to inhibit pore formation, decreased YoPro-1 uptake in all PDAC cell lines tested. This agrees with the P2X7 receptor-pore inhibitor characteristic of A438079 also described in pancreatic stellate cells, HEK293 cells and A375 human melanoma cells [17, 50, 51]. Although the pore formation is modest with high concentrations of ATP, as detected by the standard YoPro-1 analysis over 60 min, during long-term incubation with ATP, PDAC cells died with signatures of necrosis (Fig. 6). This was also reported for mesangial and SN4741 dopaminergic cells [13, 14] . Interestingly, although the pore-inhibitor A438079 had very modest effects on pore formation detected over a short period of incubation, it protected the cells from cell death during long-term incubation with high ATP concentrations (Fig. 5). Similar protective effects of the inhibitor in cell survival was detected in pancreatic stellate cells .
Let us now focus on the effect of the allosteric inhibitor, which, firstly, substantiated our arguments for functionality of P2X7R, and, second, revealed the proliferative effects of P2X7R. Thus, the specific allosteric inhibitor of P2X7R, AZ10606120 [52, 53], significantly reduced BrdU incorporation in PDAC cells (Fig. 3), which was not due to off-target cytotoxic effects (Additional file 4: Figure S3). Rather, we propose that the inhibitor decreased cell proliferation and thus revealed the proliferative potential of the P2X7 receptor over-expression in PDAC, confirming its pro-cancerous role. In “control” HPDE cells, which express lower protein levels of isoform A, the inhibitor had no effect with exogenous ATP addition. Notably in all cell lines, AZ10606120 had inhibitory effects even without added ATP, indicating that the over-expression and basal or tonic activation of P2X7R contribute to the hyperproliferative state of PDAC cells. Our findings that P2X7R is not only involved in cell death, but also in proliferation of cancer cells, are supported by studies on pancreatic stellate cells , on ovarian carcinoma cells  and also in vivo melanoma and colorectal tumor growth . Importantly, some studies already suggest that AZ10606120 can be used to abolish the proliferative phenotype of P2X7R and reduce tumor size induced by melanoma B16 cells .
The two inhibitors A438079 and AZ10606120 had seemingly opposite effects on BrdU incorporation in PDAC cells, one being protective and the other being detrimental. This helped to reveal the double role of P2X7R—in cell proliferation and cell death, both of which would occur in a population of cells. It is not clarified at this stage what molecular mechanisms and/or molecular partners interacting with the receptor could explain these seemingly disparate effects on cell survival.
In addition to cell proliferation, cancer cell migration and invasion are important in cancer behaviour. Our study shows that P2X7R is important in these two cancer hallmarks as the allosteric modulator AZ10606120 significantly reduces both PDAC cell migration (Fig. 8, Additional files 7 and 8) and invasion (Fig. 9). P2X7R also contributes to cancer cell migration and invasion as demonstrated in other types of cancer , though also other P2 receptors (e.g. P2Y2) contribute to cancer cell migration and invasion [54–56].
Taken together, our results show that multiple functions of PDAC cell lines are regulated by P2X7R: cell proliferation, cell migration and invasion, pore-formation and cell death. In a complex tumor, cells can encounter sites of lower and high ATP concentrations, e.g. at the periphery of tumor and at the core necrotic part of the tumor, respectively. Our results are in line with the model presented by Roger et al.  and with the “run or die” hypothesis in cancer, , in which cancer cells have a pro-cancerous basal activity of P2X7R that leads to proliferation and migration/invasion. Sustained activation, with high concentrations of exogenous ATP/BzATP, in a closed system (like a microplate well), which can reproduce the cancer necrotic core, leads to cancer cell death. In contrast, in an open system (like a Boyden chamber), which can reproduce the edge of the tumor, cancer cells have the possibility to “move”. ATP can be read like a stress signal and consequently cancer cells can increase the P2X7-pro-invasive phenotype and escape the harmful cancer microenvironment and invade new places. However, further investigations are needed to clarify the role of P2X7R in a complex solid tumor microenvironment, such as that of pancreatic cancer, and importantly to explore the potential interaction between P2X7R expressing cells—PDAC, PSCs, and immune cells, and as a recent report also suggests, cancer stem cells . In order to develop drug therapies, it will be important to resolve in which cell type the P2X7R-related events dominate cancer progression, as for example studied recently by Adinolfi et al. .
In conclusion, our study shows that at least two P2X7 receptor isoforms are expressed in PDAC and contributes to the basic cancer cell behavior in proliferation as wells as to cell death, and to cell migration and invasion. Therefore, we propose that the receptor could be exploited as a potential therapeutic target for treatment of pancreatic cancer.
Human pancreatic ductal adenocarcinoma cell lines were purchased from ATTC (Manassas, VA, USA). AsPC-1 (CRL-1682) and BxPC-3 (CRL-1687) were grown in RPMI-1640 medium, Capan-1 (HTB-79) in Iscove’s Modified DMEM (IMDM), Panc-1 (CRL-1469) in Dulbecco’s Modified Eagles Medium (DMEM) and MiaPaCa-2 (CRL-1420) in DMEM/Ham’s F12. Cell culture media contained stable glutamine, 10 % (20 % for Capan-1) fetal bovine serum (FBS) (PAA Laboratories; A15-151 Gold) plus 2.5 % of horse serum for MiaPaCa-2 (Biochrom), 100 U/ml penicillin and 100 μg/ml streptomycin. The human pancreatic duct epithelial cell line HPDE6-E6E7 (H6c7) [60, 61], which we refer to as HPDE, was obtained from Dr. Ming-Sound Tsao. HPDE cells were grown in KBM Basal Medium (Lonza, CC-3101), which is part of the KGM-Bullet Kit (Lonza, CC-3111). Cells were grown at 37 °C in a humidified atmosphere with 5 % CO2. All standard chemicals were purchased from Sigma-Aldrich unless otherwise stated.
RNA isolation, RT-PCR and real time PCR
Cells were cultured to confluence in a Petri dish and then RNA was isolated with RNeasy Mini Kit (Qiagen) according to the manufacturer’s instructions. DNase I, Qiagen was used. The cDNA was synthesized using the RevertAid First Strand cDNA synthesis kit (Fermentas). For RT-PCR cDNA, Jumpstart Taq DNA, primers and dNTP mix were used; the amplification parameters were as follows: one cycle at 95 °C for 1 min, 45 cycles at 95 °C for 20 s, 57 °C for 30 s, 72 °C for 1.15 min, one final cycle at 72 °C for 5 min. The transcripts were run electrophoretically in 1.2 % agarose gel. The real time PCR reactions were run using Roche FastStart Universal SYBR Green Master (ROX) with parameters as follows: one cycle at 50 °C for 2 min and one cycle at 95 °C for 10 min followed by 40 amplification cycles at 95 °C for 15 s, 57 °C for 1 min, 72 °C for 1 min and at the end a dissociation step at 95 °C for 15 s, 60 °C for 15 s, 95 °C for 15 s. Data were evaluated with SDS 2.4 software (Applied Biosystems). Primers were designed using Primer-BLAST (NCBI) and synthesized by TAG Copenhagen A/S, DK. Three housekeeping genes that were found quite stable in normal and cancerous pancreatic tissues  were used for normalization: β-actin, β-glucuronidase (GUSB) and glutaminyl-tRNA synthetase (QARS). The relative amount of the target mRNA was calculated from a standard curve constructed from the results of a serial dilution run on each plate, using Pfaffl method .
Cells were cultured to confluence in a Petri dish and lysed by adding 5x diluted lysis buffer (50 mM Tris-base, 0.25 M NaCl, 10 mM EDTA, 0.5 % NP40, 1 % TritonX-100, 4 mM NaF, pH 7.5) with 1x protease inhibitor. The final lysate was centrifuged at 15,000 g at 4 °C for 15 min. Protein concentration was estimated with a Coomassie protein assay. Protein samples were reduced by heating at 98 °C for 10 min with 50 mM DTT. 50 μg of proteins were loaded and run in 10 % polyacrylamide precast gels (Invitrogen) and blotted to PVDF membranes (Invitrogen). Membranes were blocked with 5 % skim milk solution in TBS-Tween 0.1 % buffer for 1 h at room temperature and incubated overnight at 4 °C with primary antibodies against P2X7R extracellular loop (1:200 rabbit polyclonal, Alomone, APR-008) and β-Actin (1:1000 mouse monoclonal C4, Santa Cruz, Sc-47778). Blots were then incubated with appropriate HRP-conjugated antibodies and developed with EZ-ECL (Biological Industries) and visualized on Fusion FX (Vilber Lourmat) and band intensity was calculated using Bio1D software.
Confocal fluorescence microscopy
Cells were grown on glass coverslip, and then fixed in 4 % paraformaldehyde for 15 min at room temperature. Cells were treated with 0.1 M TRIS-glycine (pH 7.4) for 15 min; permeabilized 0.3 % Tween-20 and blocked with 5 % BSA for 30 min. Cells were incubated with antibody against P2X7R extracellular loop (1:100 rabbit polyclonal, Alomone, APR-008) overnight at 4 °C. Then preparations were incubated with a secondary antibody conjugated to Alexa 568. DAPI (Molecular Probes) was used for nuclear staining. Fluorescence was examined with 40x 1.3 NA objective in Leica SP 5X MP confocal laser scanning microscope. Images and overlays were analyzed in Leica LAS AF software.
Cells were plated in white, clear bottom 96-well plates. ATP and 2′-3′-O-(4-benzoylbenzoyl)-ATP (BzATP) were dissolved in media and the pH was adjusted to 7.4 with NaOH. The indicated concentrations of ATP or BzATP were added with and without P2X7R inhibitors (10 μM AZ 10606120, 10 μM A438079 and 100 nM KN-62, Tocris) in 1 % serum media (0 % of serum for the experiments with low ATP concentrations—from 0.5 μM to 10 μM). After 60 h of incubation at 37 °C in a humidified atmosphere with 5 % CO2, cells were treated according to the manufacturer’s instruction of the Roche Cell Proliferation ELISA, BrdU chemiluminescence kit. Luminescence was read in FLUOstar OPTIMA (BMG Labtech).
Cell viability assays
To check the possible cytotoxicity of the inhibitor AZ10606120 (10 μM), the cell viability, was determined using Trypan blue exclusion. Panc-1 and BxPC-3 cells were grown in 6-well plates in 1 % serum. After 20 h, 40 h and 60 h of incubation at 37 °C in a humidified atmosphere with 5 % CO2, cells were incubated 10 min with Trypan blue. Bright field images were taken with Leica DMI6000B microscope and 10x objective. In order to determine the mode of two common cell deaths (apoptosis, necrosis) two assays were used. For apoptosis, Panc-1 cells were plated in white 96-well plates with clear bottom. ATP solution adjusted to pH 7.4 was added in 1 % serum media for a final concentration of 1 mM. Apoptosis inducer AT101  was used as a control. After 20 h of incubation, caspase 3/7 activation was determined. Cells were treated according to the manufacturer’s instruction of the Promega Caspase-Glo® 3/7 Assay. Luminescence was read by FLUOstar OPTIMA. For necrosis assay Panc-1 cells were grown in 35 mm glass-bottom dishes, after 20 h of treatment with ATP cells were incubated for 15 min with Annexin V-488 and Propidium Iodide (PI) (Life Technologies). Pictures were taken with 40x 1.3 NA objective in Leica SP 5X MP confocal laser scanning microscope, CLSM. Images and overlays were analyzed in Leica LAS AF software.
Cells were plated in black 96-well plates with clear bottom. When a confluence around 80–90 % was reached, the media was changed to a physiological buffer (140 mM NaCl, 10 mM HEPES, 1 mM MgCl2, 0.4 mM KH2PO4, 1.6 mM K2HPO4, 1.5 mM CaCl2) with 11.1 mM of glucose for AsPc-1 and BxPC-3 and 25 mM for Panc-1. Cells were incubated with AZ10606120 (10 μM) or A438079 (10 μM) for 1 h. Then cells were incubated with Yo-Pro-1 Iodide (2.5 μM, Molecular Probes) for 15 min. ATP was dissolved in a physiological buffer and the indicated concentrations were added. Ionomycin (5 μM) was added at the end of each experiment. Fluorescence was read every 10 min by FLUOstar OPTIMA.
Wound healing assay
The scratch assay was performed in two different methods. In the first method, cells were grown to confluence in 96-well Essen ImageLock plate, and then incubated with 10 μM AZ10606120 for 1 h and 5 μM aphidicolin (to stop proliferation). The wounds were made simultaneously in all wells with a 96-pin WoundMaker (Essen BioScience), washed with PBS and phase contrast pictures were taken every 2 h for 24 h in the IncuCyte ZOOM Kinetic Imaging System. Pictures were processed with the IncuCyte software using the relative wound density (%RWD) option, which measures the density of the wound with respect to the density of the cell region. The program uses the following formula: %RWD = 100 × w(t) − w(0)/c(t) − w(t); where, w(t) is the density of wounded area at time t and c(t) is the density of cell region at time t. To avoid cells damage, a second method was used. Ibidi biocompatible silicone culture-insert was stuck in the center of a 35 mm Petri dish and cells were plated in the same number in the two chambers. When the confluence was reached, the insert was removed and afterwards media with and without AZ10606120 (10 μM) was added. 10x phase contrast pictures were taken every 1 h for 24 h in the Nikon BioStation IM-Q that allowed a temperature- and gas-controlled environment. Images were analyzed by Nikon NIS-Elements AR 4.13.03 software.
The inserts for 24-well plates (transparent PET membrane, 8.0 μm pore size, Falcon) were coated with Geltrex Matrix (Invitrogen). 30.000 Panc-1 cells with aphidicolin (5 μM) and with/without AZ10606120 (10 μM), BzATP (10 μM) and ATP (100 μM) were placed in the upper chamber in 1 % of serum, and media with 10 % of serum was added in the lower chamber. After 24 h incubation at 37 °C in a humidified atmosphere with 5 % CO2, cells were fixed in cold methanol and stained with Crystal Violet. Bright field images were taken with 10x objective in Leica DMI6000B microscope. Cells were counted by ImageJ, NIH.
Chemicals and statistics
All chemicals/kits were purchased from Sigma-Aldrich unless otherwise stated. Data are shown as mean values ± standard error of mean (SEM) and n represents the number of biological replicates. Statistical analysis on data was performed by using Students t-test and One-way Analysis of Variance (ANOVA) with Holm-Sidak method using SigmaPlot 11.0. Data were analyzed in Origin or Microsoft Excel.
We are grateful to Dr. M.S. Tsao, University Health Network in Toronto, for the gift of HPDE cells. Greatly appreciated is technical assistance of Pernille Roshof and Nynne M. Christensen. Special thanks to Prof. Henriette Pilegaard for the fruitful discussions and for providing the Real time PCR machine. Images were taken at the Center for Advanced Bioimaging (CAB) the University of Copenhagen. This work was funded by FP7 Marie Curie Initial Training Network “IonTraC” (Grant Agreement No. 289648) and Danish Council for Independent Research | Natural Sciences (0602-01527B and 4002-00162), Carlsberg Foundation (2013-01-0312).
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Bardeesy N, DePinho RA. Pancreatic cancer biology and genetics. Nat Rev Cancer. 2002;2:897–909.View ArticlePubMedGoogle Scholar
- Partensky C. Toward a better understanding of pancreatic ductal adenocarcinoma: glimmers of hope? Pancreas. 2013;42:729–39.View ArticlePubMedGoogle Scholar
- Rahib L, Smith BD, Aizenberg R, Rosenzweig AB, Fleshman JM, Matrisian LM. Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. Cancer Res. 2014;74:2913–21.View ArticlePubMedGoogle Scholar
- Feig C, Gopinathan A, Neesse A, Chan DS, Cook N, Tuveson DA. The pancreas cancer microenvironment. Clin Cancer Res. 2012;18:4266–76.PubMed CentralView ArticlePubMedGoogle Scholar
- Allen M, Louise JJ. Jekyll and Hyde: the role of the microenvironment on the progression of cancer. J Pathol. 2011;223:162–76.PubMedGoogle Scholar
- Roger S, Pelegrin P. P2X7 receptor antagonism in the treatment of cancers. Expert Opin Investig Drugs. 2011;20:875–80.View ArticlePubMedGoogle Scholar
- Stagg J, Smyth MJ. Extracellular adenosine triphosphate and adenosine in cancer. Oncogene. 2010;29:5346–58.View ArticlePubMedGoogle Scholar
- Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One. 2008;3:e2599.PubMed CentralView ArticlePubMedGoogle Scholar
- Coddou C, Yan Z, Obsil T, Huidobro-Toro JP, Stojilkovic SS. Activation and regulation of purinergic P2X receptor channels. Pharmacol Rev. 2011;63:641–83.PubMed CentralView ArticlePubMedGoogle Scholar
- Sluyter R, Stokes L. Significance of P2X7 receptor variants to human health and disease. Recent Pat DNA Gene Seq. 2011;5:41–54.View ArticlePubMedGoogle Scholar
- Surprenant A, Rassendren F, Kawashima E, North RA, Buell G. The cytolytic P2Z receptor for extracellular ATP identified as a P2X receptor (P2X7). Science. 1996;272:735–8.View ArticlePubMedGoogle Scholar
- Virginio C, MacKenzie A, North RA, Surprenant A. Kinetics of cell lysis, dye uptake and permeability changes in cells expressing the rat P2X7 receptor. J Physiol. 1999;519(Pt 2):335–46.PubMed CentralView ArticlePubMedGoogle Scholar
- Schulze-Lohoff E, Hugo C, Rost S, Arnold S, Gruber A, Brune B, et al. Extracellular ATP causes apoptosis and necrosis of cultured mesangial cells via P2Z/P2X7 receptors. Am J Physiol. 1998;275:F962–71.PubMedGoogle Scholar
- Jun DJ, Kim J, Jung SY, Song R, Noh JH, Park YS, et al. Extracellular ATP mediates necrotic cell swelling in SN4741 dopaminergic neurons through P2X7 receptors. J Biol Chem. 2007;282:37350–8.View ArticlePubMedGoogle Scholar
- Baricordi OR, Melchiorri L, Adinolfi E, Falzoni S, Chiozzi P, Buell G, et al. Increased proliferation rate of lymphoid cells transfected with the P2X(7) ATP receptor. J Biol Chem. 1999;274:33206–8.View ArticlePubMedGoogle Scholar
- Bianco F, Ceruti S, Colombo A, Fumagalli M, Ferrari D, Pizzirani C, et al. A role for P2X7 in microglial proliferation. J Neurochem. 2006;99:745–58.View ArticlePubMedGoogle Scholar
- Haanes KA, Schwab A, Novak I. The P2X7 receptor supports both life and death in fibrogenic pancreatic stellate cells. PLoS One. 2012;7:e51164.PubMed CentralView ArticlePubMedGoogle Scholar
- Adinolfi E, Callegari MG, Ferrari D, Bolognesi C, Minelli M, Wieckowski MR, et al. Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell. 2005;16:3260–72.PubMed CentralView ArticlePubMedGoogle Scholar
- Adinolfi E, Cirillo M, Woltersdorf R, Falzoni S, Chiozzi P, Pellegatti P, et al. Trophic activity of a naturally occurring truncated isoform of the P2X7 receptor. FASEB J. 2010;24:3393–404.View ArticlePubMedGoogle Scholar
- Adinolfi E, Melchiorri L, Falzoni S, Chiozzi P, Morelli A, Tieghi A, et al. P2X7 receptor expression in evolutive and indolent forms of chronic B lymphocytic leukemia. Blood. 2002;99:706–8.View ArticlePubMedGoogle Scholar
- Zhang XJ, Zheng GG, Ma XT, Yang YH, Li G, Rao Q, et al. Expression of P2X7 in human hematopoietic cell lines and leukemia patients. Leuk Res. 2004;28:1313–22.View ArticlePubMedGoogle Scholar
- Solini A, Cuccato S, Ferrari D, Santini E, Gulinelli S, Callegari MG, et al. Increased P2X7 receptor expression and function in thyroid papillary cancer: a new potential marker of the disease? Endocrinology. 2008;149:389–96.View ArticlePubMedGoogle Scholar
- Greig AV, Linge C, Healy V, Lim P, Clayton E, Rustin MH, et al. Expression of purinergic receptors in non-melanoma skin cancers and their functional roles in A431 cells. J Invest Dermatol. 2003;121:315–27.View ArticlePubMedGoogle Scholar
- White N, Butler PE, Burnstock G. Human melanomas express functional P2 X(7) receptors. Cell Tissue Res. 2005;321:411–8.View ArticlePubMedGoogle Scholar
- White N, Knight GE, Butler PE, Burnstock G. An in vivo model of melanoma: treatment with ATP. Purinergic Signal. 2009;5:327–33.PubMed CentralView ArticlePubMedGoogle Scholar
- Di Virgilio F, Ferrari D, Adinolfi E. P2X(7): a growth-promoting receptor-implications for cancer. Purinergic Signal. 2009;5:251–6.PubMed CentralView ArticlePubMedGoogle Scholar
- Adinolfi E, Raffaghello L, Giuliani AL, Cavazzini L, Capece M, Chiozzi P, et al. Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res. 2012;72:2957–69.View ArticlePubMedGoogle Scholar
- Hansen MR, Krabbe S, Novak I. Purinergic receptors and calcium signalling in human pancreatic duct cell lines. Cell Physiol Biochem. 2008;22:157–68.View ArticlePubMedGoogle Scholar
- Novak I, Jans IM, Wohlfahrt L. Effect of P2X(7) receptor knockout on exocrine secretion of pancreas, salivary glands and lacrimal glands. J Physiol. 2010;588:3615–27.PubMed CentralView ArticlePubMedGoogle Scholar
- Novak I, Nitschke R, Amstrup J. Purinergic receptors have different effects in rat exocrine pancreas. Calcium signals monitored by fura-2 using confocal microscopy. Cell Physiol Biochem. 2002;12:83–92.View ArticlePubMedGoogle Scholar
- Kunzli BM, Nuhn P, Enjyoji K, Banz Y, Smith RN, Csizmadia E, et al. Disordered pancreatic inflammatory responses and inhibition of fibrosis in CD39-null mice. Gastroenterology. 2008;134:292–305.PubMed CentralView ArticlePubMedGoogle Scholar
- Apte MV, Pirola RC, Wilson JS. Pancreatic stellate cells: a starring role in normal and diseased pancreas. Front Physiol. 2012;3:344.PubMed CentralView ArticlePubMedGoogle Scholar
- Kunzli BM, Berberat PO, Giese T, Csizmadia E, Kaczmarek E, Baker C, et al. Upregulation of CD39/NTPDases and P2 receptors in human pancreatic disease. Am J Physiol Gastrointest Liver Physiol. 2007;292:G223–30.View ArticlePubMedGoogle Scholar
- Brody JR, Witkiewicz A, Williams TK, Kadkol SS, Cozzitorto J, Durkan B, et al. Reduction of pp 32 expression in poorly differentiated pancreatic ductal adenocarcinomas and intraductal papillary mucinous neoplasms with moderate dysplasia. Mod Pathol. 2007;20:1238–44.View ArticlePubMedGoogle Scholar
- Blanchard JA, Barve S, Joshi-Barve S, Talwalker R, Gates Jr LK. Antioxidants inhibit cytokine production and suppress NF-kappaB activation in CAPAN-1 and CAPAN-2 cell lines. Dig Dis Sci. 2001;46:2768–72.View ArticlePubMedGoogle Scholar
- Al Shemaili J, Mensah-Brown E, Parekh K, Thomas SA, Attoub S, Hellman B, et al. Frondoside A enhances the antiproliferative effects of gemcitabine in pancreatic cancer. Eur J Cancer. 2014;50:1391–8.View ArticlePubMedGoogle Scholar
- Ouyang H, Mou L, Luk C, Liu N, Karaskova J, Squire J, et al. Immortal human pancreatic duct epithelial cell lines with near normal genotype and phenotype. Am J Pathol. 2000;157:1623–31.PubMed CentralView ArticlePubMedGoogle Scholar
- Hiken JF, Steinberg TH. ATP downregulates P2X7 and inhibits osteoclast formation in RAW cells. Am J Physiol Cell Physiol. 2004;287:C403–12.View ArticlePubMedGoogle Scholar
- Alves LA, Bezerra RJ, Faria RX, Ferreira LG, Da Silva FV. Physiological roles and potential therapeutic applications of the P2X7 receptor in inflammation and pain. Molecules. 2013;18:10953–72.View ArticlePubMedGoogle Scholar
- Luo J, Lee S, Wu D, Yeh J, Ellamushi H, Wheeler AP, et al. P2X7 purinoceptors contribute to the death of Schwann cells transplanted into the spinal cord. Cell Death Dis. 2013;4:e829.PubMed CentralView ArticlePubMedGoogle Scholar
- Vazquez-Cuevas FG, Martinez-Ramirez AS, Robles-Martinez L, Garay E, Garcia-Carranca A, Perez-Montiel D, et al. Paracrine stimulation of P2X7 receptor by ATP activates a proliferative pathway in ovarian carcinoma cells. J Cell Biochem. 2014;115:1955–66.PubMedGoogle Scholar
- Jin H, Seo J, Eun SY, Joo YN, Park SW, Lee JH, et al. P2Y R activation by nucleotides promotes skin wound healing process. Exp Dermatol. 2014;23(7):480–5.View ArticlePubMedGoogle Scholar
- Xie R, Xu J, Wen G, Jin H, Liu X, Yang Y, et al. P2Y2 Nucleotide Receptor Mediates the Proliferation and Migration of Human Hepatocellular Carcinoma Cells Induced by ATP. J Biol Chem. 2014;289(27):19137–49.PubMed CentralView ArticlePubMedGoogle Scholar
- Zhu L, Shi G, Schmidt CM, Hruban RH, Konieczny SF. Acinar cells contribute to the molecular heterogeneity of pancreatic intraepithelial neoplasia. Am J Pathol. 2007;171:263–73.PubMed CentralView ArticlePubMedGoogle Scholar
- Li X, Zhou L, Feng YH, Abdul-Karim FW, Gorodeski GI. The P2X7 receptor: a novel biomarker of uterine epithelial cancers. Cancer Epidemiol Biomarkers Prev. 2006;15:1906–13.PubMed CentralView ArticlePubMedGoogle Scholar
- Qiu Y, Li WH, Zhang HQ, Liu Y, Tian XX, Fang WG. P2X7 mediates ATP-driven invasiveness in prostate cancer cells. PLoS One. 2014;9:e114371.PubMed CentralView ArticlePubMedGoogle Scholar
- Jelassi B, Chantome A, Alcaraz-Perez F, Baroja-Mazo A, Cayuela ML, Pelegrin P, et al. P2X(7) receptor activation enhances SK3 channels- and cystein cathepsin-dependent cancer cells invasiveness. Oncogene. 2011;30:2108–22.View ArticlePubMedGoogle Scholar
- Smith SM, Mitchell GS, Friedle SA, Sibigtroth CM, Vinit S, Watters JJ. Hypoxia Attenuates Purinergic P2X Receptor-Induced Inflammatory Gene Expression in Brainstem Microglia. Hypoxia (Auckl) 2013. 2013.Google Scholar
- Khadra A, Tomic M, Yan Z, Zemkova H, Sherman A, Stojilkovic SS. Dual gating mechanism and function of P2X7 receptor channels. Biophys J. 2013;104:2612–21.PubMed CentralView ArticlePubMedGoogle Scholar
- Fowler BJ, Gelfand BD, Kim Y, Kerur N, Tarallo V, Hirano Y, et al. Nucleoside reverse transcriptase inhibitors possess intrinsic anti-inflammatory activity. Science. 2014;346:1000–3.PubMed CentralView ArticlePubMedGoogle Scholar
- Fischer W, Urban N, Immig K, Franke H, Schaefer M. Natural compounds with P2X7 receptor-modulating properties. Purinergic Signal. 2013;10:313–26.PubMed CentralView ArticlePubMedGoogle Scholar
- Michel AD, Chambers LJ, Clay WC, Condreay JP, Walter DS, Chessell IP. Direct labelling of the human P2X7 receptor and identification of positive and negative cooperativity of binding. Br J Pharmacol. 2007;151:103–14.View ArticlePubMedGoogle Scholar
- Michel AD, Chambers LJ, Walter DS. Negative and positive allosteric modulators of the P2X(7) receptor. Br J Pharmacol. 2008;153:737–50.PubMed CentralView ArticlePubMedGoogle Scholar
- Klepeis VE, Weinger I, Kaczmarek E, Trinkaus-Randall V. P2Y receptors play a critical role in epithelial cell communication and migration. J Cell Biochem. 2004;93:1115–33.View ArticlePubMedGoogle Scholar
- Li WH, Qiu Y, Zhang HQ, Liu Y, You JF, Tian XX et al. P2Y2 receptor promotes cell invasion and metastasis in prostate cancer cells. Br J Cancer. 2013;109:1666-1675.Google Scholar
- Boucher I, Rich C, Lee A, Marcincin M, Trinkaus-Randall V. The P2Y2 receptor mediates the epithelial injury response and cell migration. Am J Physiol Cell Physiol. 2010;299:C411–21.PubMed CentralView ArticlePubMedGoogle Scholar
- Roger S, Jelassi B, Couillin I, Pelegrin P, Besson P, Jiang L. Understanding the roles of the P2X7 receptor in solid tumour progression and therapeutic perspectives. Biochim Biophys Acta. 2014;1848:2584–602.Google Scholar
- Sainz Jr B, Alcala S, Garcia E, Sanchez-Ripoll Y, Azevedo MM, Cioffi M, et al. Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Gut. 2015;64(12):1921–35.View ArticlePubMedGoogle Scholar
- Adinolfi E, Capece M, Franceschini A, Falzoni S, Giuliani AL, Rotondo A, et al. Accelerated tumor progression in mice lacking the ATP receptor P2X7. Cancer Res. 2015;75:635–44.View ArticlePubMedGoogle Scholar
- Radulovich N, Qian JY, Tsao MS. Human pancreatic duct epithelial cell model for KRAS transformation. Methods Enzymol. 2008;439:1–13.View ArticlePubMedGoogle Scholar
- Leung L, Radulovich N, Zhu CQ, Wang D, To C, Ibrahimov E, et al. Loss of canonical Smad4 signaling promotes KRAS driven malignant transformation of human pancreatic duct epithelial cells and metastasis. PLoS One. 2013;8:e84366.PubMed CentralView ArticlePubMedGoogle Scholar
- Rubie C, Kempf K, Hans J, Su T, Tilton B, Georg T, et al. Housekeeping gene variability in normal and cancerous colorectal, pancreatic, esophageal, gastric and hepatic tissues. Mol Cell Probes. 2005;19:101–9.View ArticlePubMedGoogle Scholar
- Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.PubMed CentralView ArticlePubMedGoogle Scholar
- Zerp SF, Stoter R, Kuipers G, Yang D, Lippman ME, van Blitterswijk WJ, et al. AT-101, a small molecule inhibitor of anti-apoptotic Bcl-2 family members, activates the SAPK/JNK pathway and enhances radiation-induced apoptosis. Radiat Oncol. 2009;4:47.PubMed CentralView ArticlePubMedGoogle Scholar